Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liridon Abduli

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Blood Advances|October 7, 2020
TNFR2 is required for RIP1-dependent cell death in human leukemiaJúlia Aguadé-Gorgorió, Scott McComb, Cornelia Eckert, et al.
Blood Cancer Journal|June 28, 2020
Repurposing anthelmintic agents to eradicate resistant leukemiaCaterina Mezzatesta, Liridon Abduli, Anna Guinot, et al.
Cancer Immunology Research|April 29, 2024
The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem CellsMatteo Bianchi, Christian Reichen, Amelie Croset, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Blood Advances|October 7, 2020
TNFR2 is required for RIP1-dependent cell death in human leukemiaJúlia Aguadé-Gorgorió, Scott McComb, Cornelia Eckert, et al.
Blood Cancer Journal|June 28, 2020
Repurposing anthelmintic agents to eradicate resistant leukemiaCaterina Mezzatesta, Liridon Abduli, Anna Guinot, et al.
Cancer Immunology Research|April 29, 2024
The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem CellsMatteo Bianchi, Christian Reichen, Amelie Croset, et al.
Pageof 1